Predictability of individualized dosage regimens of carbamazepine and valproate mono- and combination therapy

Journal of Clinical Pharmacy and Therapeutics

Volumn 36, Issue 5, 2011, Pages 625-636

  Bondareva, I B ^a   Jelliffe, R W ^b   Andreeva, O V ^a   Bondareva, K I ^c  

^a FEDERAL RESEARCH AND CLINICAL CENTER OF PHYSICAL CHEMICAL MEDICINE OF FEDERAL MEDICAL BIOLOGICAL AGENCY   (Russian Federation)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MOSCOW STATE UNIVERSITY   (Russian Federation)

Author keywords

pharmacokinetic pharmacodynamic modelling; therapeutic drug monitoring; validation

Indexed keywords

CARBAMAZEPINE; VALPROIC ACID;

ACCURACY; ADULT; BAYES THEOREM; DISTRIBUTION VOLUME; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG ELIMINATION; DRUG MONITORING; DRUG SAFETY; EPILEPSY; HUMAN; LINEAR REGRESSION ANALYSIS; MAJOR CLINICAL STUDY; MONOTHERAPY; REVIEW; VALIDATION PROCESS;

ADULT; AGED; ANTICONVULSANTS; BAYES THEOREM; CARBAMAZEPINE; CHRONIC DISEASE; DATABASES, FACTUAL; DEMOGRAPHY; DRUG MONITORING; DRUG THERAPY, COMBINATION; EPILEPSY; FORECASTING; HUMANS; MEDICAL RECORDS; MIDDLE AGED; MODELS, BIOLOGICAL; OUTPATIENTS; REPRODUCIBILITY OF RESULTS; RETROSPECTIVE STUDIES; SEIZURES; SOFTWARE; VALPROIC ACID; YOUNG ADULT;

EID: 80052841299     PISSN: 02694727     EISSN: 13652710     Source Type: Journal    
DOI: 10.1111/j.1365-2710.2010.01215.x     Document Type: Review

References (27)

1. Affolter N, Krähenbühl S, Schlienger RG, (2003) Appropriateness of serum level determinations of antiepileptic drugs. Swiss Medical Weekly, 133, 591-597. (Pubitemid 38017062)
2. Bayard D, Jelliffe R, (2004) A Bayesian approach to tracking patients having changing pharmacokinetic parameters. Journal of Pharmacokinetics and Pharmacodynamics, 31, 75-107. (Pubitemid 38870191)
3. Gomez Bellver MJ, Garcia Sanchez MJ, Alonso Gonzalez AC, et al. (1993) Plasma protein binding kinetics of valproic acid over a broad dosage range: therapeutic implications. Journal of Clinical Pharmacy and Therapeutics, 18, 191-197. (Pubitemid 23187045)
4. Bondareva IB, Andreeva O, (2009) Population Pharmacokinetics of Carbamazepine and Estimation of Influencing Factors. Presentation at the PAGE 18 Meeting, St Petersburg, Russia, June 2009.
5. Bondareva IB, Jelliffe RW, Gusev EI, Guekht AB, Melikyan EG, Belousov YB, (2006) Population pharmacokinetic modeling of carbamazepine in epileptic elderly patients. Journal of Clinical Pharmacy and Therapeutics, 31, 1-11.
6. Bondareva IB, Jelliffe RW, Sokolov AV, Tischenkova IF, (2004) Nonparametric population modeling of valproate pharmacokinetics in epileptic patients using routine serum monitoring data: implications for dosage. Journal of Clinical Pharmacy and Therapeutics, 29, 1-16.
7. Bondareva IB, Sokolov AV, Tischenkova IF, Jelliffe RW, (2001) Population pharmacokinetic modeling of carbamazepine by using the iterative bayesian (IT2B) and the nonparametric em (NPEM) algorithms: implications for dosage. Journal of Clinical Pharmacy and Therapeutics, 26, 213-223. (Pubitemid 32592553)
8. Bondareva K, (2009) External Validation of Population Models for Carbamazepine Pharmacokinetics and the Individualizing Carbamazepine Dosage Regimen Procedure. Presentation at the PAGE 18 Meeting, St Petersburg, Russia, June 2009.
9. Brodie MJ, Dichter MA, (1996) Drug therapy-antiepileptic drugs. New England Journal of Medicine, 334, 168-175.
10. Dean JCh, (1997) Valproate. In:, Wyllie E, ed. The treatment of epilepsy: principles and practice, 2nd edn. Baltimore: Willians & Wilkins, 824-832.
11. Deckers CL, Czuczwar SJ, Hekster YA, et al. (2000) Selection of antiepileptic drug polytherapy based on mechanisms of action: the evidence reviewed. Epilepsia, 41, 1364-1374.
12. Gidal BE, (2001) Pharmacokinetics of the new antiepileptic drugs. The American Journal of Managed Care, 7, S215-S220.
13. Gram L, Flachs H, Wurtz-Jorgensen A, et al. (1979) Sodium valproate, serum level and clinical effect in epilepsy: a controlled study. Epilepsia, 20, 303-311. (Pubitemid 9168942)
14. Harden CL, Zisfein J, Atos-Radzion EC, Tuchman AJ, (1993) Combination valproate-carbamazepine therapy in partial epilepsies resistant to carbamazepine monotherapy. Journal of Epilepsy, 6, 91-94. (Pubitemid 23144175)
15. Holford NHG, (1999) Target concentration intervention: beyond Y2K. British Journal of Clinical Pharmacology, 48, 9-13. (Pubitemid 29296656)
16. Jelliffe RW, Schumitzky A, Van Guilder M, Jiang F, (1996) User Manual for Version 10.7 of USC*PACK Collection of PC Programs. Laboratory of Applied Pharmacokinetics, University of Southern California, School of Medicine, Los Angeles, CA, USA.
17. Karlsson MO, Sheiner LB, (1993) The importance of modeling interoccasion variability in population pharmacokinetic analyses. Journal of Pharmacokinetics and Biopharmaceutics, 21, 735-750. (Pubitemid 24052760)
18. Kondo T, Otani K, Hirano T, et al. (1990) The effects of phenytoin and carbamazepine on serum concentrations of monounsaturated metabolites of valproic acid. British Journal of Clinical Pharmacology, 29, 116-119. (Pubitemid 20130560)
19. Loiseau P, (1993) Sustained Release Valproate-A Review. A Sanofi Winthrop Sattelite Symposium presented at the Bethel-Cleveland Epilepsy Symposium, Bielefild, Germany, 10 March 1993.
20. McKee PJW, Blacklaw J, Butler RA, et al. (1992) Variability and clinical relevance of the interaction between sodium valproate and carbamazepine in epileptic patients. Epilepsy Research, 11, 193-198.
21. Neels HM, Sierens AC, Naelaerts K, (2004) Therapeutic drug monitoring of old and newer antiepileptic drugs. Clinical Chemistry and Laboratory Medicine, 42, 1228-1255. (Pubitemid 39600327)
22. Patsalos PN, (1999) New antiepileptic drugs. Annals of Clinical Biochemistry, 36, 10-19. (Pubitemid 29041619)
23. Patsalos PN, Froscher W, Pisani F, et al. (2002) The importance of drug interactions in epilepsy therapy. Epilepsia, 43, 365-385. (Pubitemid 34297175)
24. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Center for Biologics Evaluation and Research (CBER) (1999) Population Pharmacokinetics Guidance for Industry. Rockville, MD.
25. Sillampaa M, (1997) Carbamazepine. In:, Wyllie E, ed. The treatment of epilepsy: principles and practice, 2nd edn. Baltimore: Willians & Wilkins, 802-824.
26. Shen DD,. (1999) Absorption, distribution, and excretion. In:, Loscher W, ed. Valproate. Birkhauser Verlag, Basel-Boston-Berlin, 77-90.
27. Vinks A,: Keynote speech at the 11th International Congress of TDM & Clinical Toxicology October 3-8, 2009, Montreal, Canada. (accessed 24 September 2010).